Personalized mRNA vaccine combined with Keytruda shows 49% reduction in melanoma recurrence risk
By
Allison Aubrey
Crackling crust, pillowy middle. The kind of bagel that earns a second cup of coffee.
Summary
An 80-year-old melanoma patient, Connie Franciosi, participated in a clinical trial testing an mRNA cancer vaccine (mRNA-4157/V940) combined with the immunotherapy drug Keytruda. The study found the personalized mRNA vaccine significantly reduced the risk of recurrence and death from melanoma by 49% after three years compared to Keytruda alone. The vaccine is custom-built for each patient based on their tumor's genetic mutations, training the immune system to recognize and attack cancer cells. Researchers are now expanding trials to other cancers including lung, bladder, and kidney cancer, marking a promising new frontier for mRNA technology beyond COVID-19.
Key quotes
· 3 pulledIt was considered a late diagnosis.
This is a very exciting time for cancer research. We are seeing a lot of progress in the field of cancer vaccines.
The vaccine is designed to train the immune system to recognize and attack cancer cells that are specific to each patient's tumor.
You might also wanna read
Personalized mRNA Cancer Vaccine Shows 49% Risk Reduction at 5-Year Follow-up
Moderna and Merck report promising 5-year follow-up results for their personalized mRNA cancer vaccine combined with Keytruda immunotherapy.
arstechnica.com·4mo ago
Scientists Develop Universal Cancer Vaccine Using mRNA Technology
Scientists have developed a 'universal cancer vaccine' using mRNA technology that can train the immune system to target any type of cancer,
newatlas.com·10mo ago
Study Examines Association Between mRNA COVID-19 Vaccination and 4-Year All-Cause Mortality in French Adults Aged 18-59
This cohort study analyzes data from over 28 million French adults aged 18-59 to examine the association between mRNA COVID-19 vaccination a
jamanetwork.com·6mo ago
Long-term HPV vaccine effectiveness study shows stable protection against targeted virus types in Danish women vaccinated as girls
This study examines the long-term effectiveness of HPV vaccination in Danish women who received the 4-valent HPV vaccine as girls in 2008. T
eurosurveillance.org·5mo agoUndisclosed Deaths in the Pfizer mRNA Covid-19 Vaccine Trial [pdf]
Engineered immunotherapy drug eliminates aggressive metastatic cancers in clinical trial
Researchers at Rockefeller University have developed an engineered CD40 agonist antibody that successfully eliminated aggressive metastatic
rockefeller.edu·9mo ago